

1 [[Original Investigation]]

2 Closure of Long Surgical Incisions 3 with A Novel Hemostatic Tissue 4 Adhesive in Porcine Skin Model

5 Ariel Neiman, MD; Inbar Eshkol-Yogev, DMD, PhD; Aviad Keren, PhD; Maytal Fook, PhD;
6 Oded Pinkas, PhD; Nyra Goldstein, BSc; Amos Gilhar, MD; Meital Zilberman, PhD; and
7 Yehuda Ullmann, MD

8 Ariel Neiman, MD is Attending Plastic Surgeon and Head of Breast Reconstruction and
9 Microsurgery, Meir Health Center, Kfar Saba, Israel. Inbar Eshkol-Yogev, DMD, PhD is
10 Clinical Lecturer, Eastman Dental Institute, UCL, London, UK; Aviad Keren, PhD is Lab
11 Manager, Israel Institute of Technology, Haifa, Israel. Maytal Fook, PhD is Director of
12 Food Technology and Product Development, Aleph Farms, Rehovot, Israel. Oded Pinkas,
13 PhD, is Director of Process Development, NanoGhost, Netanya, Israel. Nyra Goldstein,
14 BSc, is Researcher, Biond Biologics, Misgave Industrial Park, Israel. Also at Israel Institute
15 of Technology, Amos Gilhar, MD, is Director, Skin Research Laboratory, Ruth & Bruce
16 Rappaport Faculty of Medicine. Meital Zilberman, PhD is Professor of Biomedical
17 Engineering, Tel-Aviv University, Tel-Aviv, Israel. Yehuda Ullmann, MD is Director of the
18 Surgical Division, Rambam Health Care Campus, Haifa. **Acknowledgment:** The authors
19 are grateful to the Momentum Fund, Ramot at Tel-Aviv University, for supporting this
20 research. The authors have disclosed no financial relationships related to this article.
21 Submitted March 26, 2023; accepted in revised form June 27, 2023.

22

23 **ABSTRACT**

24 **Objective:** Skin adhesives offer many advantages over traditional wound closure
25 devices. Recently, the current research group reported novel tissue adhesives composed
26 of natural polymers (gelatin and alginate), which are biocompatible with mechanical
27 properties suitable for tissue adhesion. The objective of the present study was to
28 conduct clinical and histologic assessment of this hemostatic bioadhesive in the healing

29 of long skin incisions (≥ 4 cm) in comparison with traditional and commercially available
30 methods.

31 **Methods:** Researchers created 24 long incisions on the ventral side of two domestic
32 pigs to compare four different treatment modalities: two novel topical bioadhesives
33 based on gelatin and alginate combined with hemostatic agent Kaolin, nylon sutures,
34 and commercial tissue adhesive N-butyl-2-cyanoacrylate. The bioadhesive compounds
35 were spread on the incision surface and then either mixed manually or by using a
36 double-headed syringe. After 14 days, clinical and histologic measurements were
37 performed to evaluate the healing phase of the wounds.

38 **Results:** The formulation that contained a relatively low crosslinker concentration
39 demonstrated superior results to the formulation that contained a standard crosslinker
40 concentration. However, no significant statistical differences were observed compared
41 with the two control incisions (sutures and commercial adhesive N-butyl-2-
42 cyanoacrylate). This was verified by immunohistochemical analysis for epithelial
43 integrity and scar formation as well as by clinical assessment.

44 **Conclusions:** This newly developed bioadhesive demonstrated suitable properties
45 for the closure of long incisions in a porcine skin model.

46 **Keywords:** bioadhesive, cyanocrylate, hydrogel, incision, kaolin, skin, wound closure,
47 wound healing

48

49 **INTRODUCTION**

50 Every year, millions of people suffer traumatic wounds,
51 such as skin lacerations, or surgical wounds that cause
52 disruption of organs, connective tissue, muscles, and
53 tendons.¹ Although small skin lacerations (<4 cm) can heal
54 spontaneously without intervention, large skin lacerations
55 (≥ 4 cm), especially those that are irregular shaped or deep
56 are more complex and may exhibit impaired or delayed
57 healing. In these cases, sutures are the traditional
58 treatment for wound closure and bleeding control because of
59 their high tensile strength and low dehiscence. However,
60 inconvenience, pain, relatively slow handling, the need for
61 removal in some cases, and concern over possible disease
62 transmission through the use of needles are major
63 disadvantages of suturing. Other techniques have been
64 suggested to address these issues, including the use of
65 clips, staples, tapes, hemostasis agents, and tissue
66 bioadhesives.^{2,3} Although tissue bioadhesives are an adequate
67 solution for treating small lacerations, their use is
68 limited in larger wounds mainly due to lower strength and
69 flexibility and cytotoxicity issues⁴.

70 Tissue bioadhesives represent a group of compounds
71 that can be applied locally for a variety of indications,
72 including bleeding control, wound closure, hemostasis,
73 sealing air and body fluid leaks, repair of fistulas and
74 aortic dissections, external fixation of devices, and drug
75 delivery.^{5,6} N-butyl-2-cyanoacrylate, fibrin, and

76 polyethylene glycol-based bioadhesives are among the most
77 commonly used surgical bioadhesives. However, none of them
78 satisfy the requirements of an ideal bioadhesive including
79 both adequate mechanical properties particularly in wet
80 environment, together with high biocompatibility.

81 Cyanoacrylates are the most widely used FDA-approved
82 bioadhesives in clinical practice.⁷ Cyanoacrylates have a
83 high bonding strength to biological tissues and rapid
84 curing time and are easy to use. However, they have been
85 limited to external or temporary applications because of
86 the toxicity of its degradation byproducts, its low
87 viscosity, and its high stiffness. All of the above can
88 cause adhesion failure, tissue irritation, and inflammatory
89 responses.¹ N-butyl-2-cyanoacrylate is rarely used for long
90 incisions, but only as a final touch on top of
91 intracuticular suturing.

92 Extensive efforts are therefore underway to develop a
93 safer, nontoxic, degradable, and hemostatic bioadhesive.
94 Recently, the present research group developed a novel
95 bioadhesive formulation based on a combination of gelatin
96 and alginate crosslinked with carbodiimide (EDC) and loaded
97 with the hemostatic agent kaolin.^{8,9}

98 Gelatin is a biocompatible, biodegradable, water-
99 soluble polypeptide that is obtained from collagen.¹⁰ It is
100 popular in medical applications such as tissue

101 bioadhesives, drug-delivery systems, and wound dressings.¹¹
102 Alginate is a naturally occurring polysaccharide, extracted
103 from brown algae.¹² It is biodegradable under normal
104 physiologic conditions and its high and controllable gel
105 porosity makes it a good candidate for protein and cell
106 delivery.¹³ However, to maintain the mechanical properties of
107 gelatin and alginate gels, they need to be crosslinked with
108 an appropriate crosslinking agent.

109 The cross-linking reaction of this system is achieved
110 using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide
111 hydrochloride (EDC). This is a zero-length crosslinker that
112 creates the cross-linking reaction and leaves urea as a
113 byproduct, which is much less toxic than formaldehyde and
114 glutaraldehyde (as are formed with cyanoacrylate use).
115 Previous studies by this research group¹¹⁻¹³ indicated that a
116 formulation containing 400 mg/ml gelatin, 10 mg/ml
117 alginate, and crosslinked EDC has high potential for wound-
118 closure applications, because of its relatively high
119 bonding strength, burst strength (sealing ability), and
120 strength of the bulk material, and suitable gelation time
121 and viscosity. This formulation was also found to be
122 biocompatible with low cytotoxicity in vitro and in vivo.¹⁴⁻
123 ¹⁶ Further studies also succeeded in lowering the
124 concentration of the crosslinker agent, using N-
125 hydroxysuccinimide (NHS), without decreasing the tissue-
126 bonding strength.¹⁷

127 Based on the researchers' previous in vitro studies,
128 in the present study they tested two bioadhesive
129 formulations (A and B)^{17,18} to evaluate the effectiveness of
130 the novel gelatin-alginate-EDC-based bioadhesive in the
131 healing process of skin incisions in a porcine skin model.
132 Whereas most studies of bioadhesives have focused on skin
133 closure of short wounds, this report focuses on the results
134 of an in vivo study comparing the novel investigational
135 tissue adhesive with sutures and other commercially
136 available skin-closure devices for epidermal closure of
137 long (≥ 4 cm) surgical incisions.

138

139 **METHODS**

140 **Materials**

141 Gelatin "type A" from porcine skin (90-110 g bloom), low
142 viscosity alginic acid sodium salt, EDC, NHS, and kaolin
143 (K1512) were purchased from Sigma-Aldrich, Rehovot, Israel.

144 **Preparation of Tissue Bioadhesives**

145 Preparation of the bioadhesives was based on dissolving 400
146 mg/mL gelatin and 10 mg/mL alginate (Gel-Al) together with
147 the hemostatic agent powder (3% w/v kaolin) in distilled
148 water, under heating up to 60 °C in order to create
149 homogenous hydrogel. The crosslinking agents (EDC and NHS)
150 were added to the Gel-Al solution containing the hemostatic

151 agent by two different methods. In the first method, the
152 polymer solution and crosslinking agent solution were
153 loaded in separate syringes and mixed in the incision site.
154 In the second method, a double-headed syringe was used to
155 mix the two solutions prior to application in the incision
156 site.

157 Two formulations were used: Formulation A (standard)
158 contained 20 mg/mL EDC, and formulation B (low EDC content)
159 contained 10 mg/mL EDC and 1 mg/mL NHS (Table 1). Both
160 formulations exhibited similar ex vivo bonding strengths of
161 approximately 30 KPa.¹⁸

162 **Animal Model and Surgical Procedures**

163 Porcine skin is anatomically and physiologically similar to
164 human skin; both have a thick epidermis and a similar
165 dermis-epidermis thickness ratio.¹⁹ They also both have
166 well-developed epithelial extensions that project into the
167 underlying connective tissue (rete pegs), papillary bodies,
168 similar dermal collagen, and rich subdermal adipose
169 tissue.¹⁹ The size, orientation, and distribution of blood
170 vessels in the pig dermis are similar to blood vessels in
171 human skin. Functionally, porcine and human skin are
172 similar in terms of epidermal turnover time, type of
173 keratinous proteins, and lipid composition. In addition,
174 human and porcine skin heal through similar physiologic
175 processes. As a result, the porcine is an excellent animal

176 model for the assessment of post-trauma wound healing
177 agents destined for use in human wounds.

178 Animal handling was conducted in accordance with
179 national guidelines and was approved by the Institutional
180 Review Board and the Institutional Committee on Animal Use,
181 Rappaport Faculty of Medicine, Technion, Israel Institute
182 of Technology.

183 The study was performed on two large white juvenile
184 domestic swine (*Sus scrofa domestica*) weighing 60 and 55
185 kg. The study was conducted in two stages, involving one
186 pig each time, allowing for a staged assessment of the
187 effects of adhesive on porcine subjects. The animals were
188 purchased from the Animal Research Institute, Kibbutz
189 Lahav, Israel. They were housed in individual pens with an
190 artificial 12-hour light/dark cycle and constant
191 temperature. The animals were acclimated for 1 week prior
192 to the study and were fed standard chow and water ad
193 libitum.

194 During the 14-day follow-up period, the animals were
195 examined daily for the following signs: food and water
196 intake, urine/feces, general appearance, and behavior. The
197 nutrition state, integument, eyes, nose and mucosa
198 membrane, lymph nodes, respiratory tract, cardiovascular
199 system, digestive system, mammary glands, and nervous
200 system were monitored once a week.

201 On the day of the experiment, the animals were
202 anesthetized with an intramuscular injection of ketamine
203 (20 mg/kg) and ACP1 (1 mg/kg), followed by induction with
204 propofol (5-7 mg/kg). After intubation, anesthesia was
205 maintained with isoflurane 2% delivered by PPV (Pulse
206 Pressure Variation) plus Fentanyl (5-10 mcg/kg/h). The
207 ventral skin surface of the animals was shaved using an
208 electric shaving machine. The skin was then disinfected
209 using a septal scrub (chlorhexidine disinfectant) and 70%
210 ethanol.

211 Twelve 10-cm-long incisions were made in each animal
212 using a #10 blade.²⁰ The 24 incisions were divided into the
213 following treatments: sutures, commercial N-butyl-2-
214 cyanoacrylate, formulation A, formulation B, formulation A
215 using a double-headed syringe, and formulation B using a
216 double-headed syringe. Sutured incisions (10 sutures per
217 incision using interrupted 3-0 nylon) and incisions treated
218 with commercial N-butyl-2-cyanoacrylate served as positive
219 controls. The 12 incisions performed on the first animal
220 were divided equally, with two incisions for each of the
221 above treatments. The 12 incisions performed on the second
222 animal were divided as follows: two incisions were treated
223 with sutures, two were treated with commercial N-butyl-2-
224 cyanoacrylate, four were treated with formulation B and
225 four were treated with formulation B using a double-headed
226 syringe.

227 For all incisions treated with N-butyl-2-cyanoacrylate
228 or the tested bioadhesive, the material was applied into
229 the incisional gaps. Mechanical pressure was then applied
230 for 30 seconds to hold the two adjacent edges of the
231 incision. Following this, researchers applied skin closure
232 strips on each wound and secured a large bandage with
233 surgical staples. After the surgical procedures, the
234 animals were treated with Tramadol (100 mg once a day) and
235 Optalgin (500 mg twice a day) for three days.

236 The animals were anesthetized again at the endpoint,
237 14 days post-operation. The incisions were photographed
238 documented, and 1 cm biopsies were taken from the center of
239 each wound and immediately fixed in phosphate-buffered
240 formalin for histological and immunohistochemical analysis.
241 The animals were then sacrificed in the standard procedure
242 by receiving an overdose of 5% isoflurane for 5
243 minutes followed by KCL (potassium chloride) IV.

244 **Histologic Analysis**

245 The skin biopsies that were fixed in phosphate-buffered
246 formalin were dehydrated with an increasing alcohol
247 gradient. The biopsies were then embedded in paraffin and
248 5- μ m thick sections were made using a Leica microtome. The
249 slides were deparaffinized and hydrated with a decreasing
250 alcohol gradient. The sections were then taken for standard
251 hematoxylin and eosin or trichrome stain (Gomori Kit,

252 Sigma-Aldrich), and were analyzed according to the
253 manufacturer's instructions.

254 The sections were observed and photographed under ×200
255 and ×400 magnification using an Olympus upright light
256 microscope. Healing analysis was conducted in a double-
257 blind manner by four separate evaluators using a
258 quantitative grading system. The sections were evaluated
259 based on structure and content. The healing criteria
260 examined included epithelial confluence, epithelialization,
261 clinical collagen assessment, scar width, and mononuclear
262 cell infiltrate. Criteria were graded on a scale of 0 to 5:
263 0 = absence, 1 = minimal presence, 2 = mild presence, 3 =
264 moderate presence, 4 = high presence and 5 = extensive
265 presence. The presented score is the average of the four
266 evaluators.

267 **Immunohistochemical Analysis**

268 Immunohistochemical analysis was performed on formalin-
269 fixed paraffin sections. The slides were deparaffinized and
270 hydrated with a decreasing alcohol gradient and immersed in
271 distilled water. The following antibodies were used: anti-
272 laminin antibody (Abcam, ab11575), Ki-67 antibody (Zymed
273 Laboratories, 7B11), and anti- α smooth muscle actin (anti-
274 α SMA) antibody (Abcam, ab5694).²¹⁻²³ For anti-laminin
275 staining, antigen retrieval was performed using 1 mM Tris-
276 EDTA buffer solution (pH 8) at 90 °C for 13 min, followed by

277 proteinase K digestion at 37 °C for 10 min. For anti- α SMA
278 and Ki-67 staining, antigen retrieval was performed using 1
279 mM Tris-EDTA buffer solution (pH 8) at 90 °C for 20 minutes.
280 The sections were then blocked with suitable serum for 30
281 minutes, followed by 14 hours of incubation at 4 °C with the
282 primary antibody. This was followed by incubation with an
283 appropriate biotinylated secondary antibody, streptavidin-
284 peroxidase conjugate, and S-(2-aminoethyl)-l-cysteine as
285 substrate (Histostain-SP kit; Zymed Laboratories).
286 Counterstaining was performed with hematoxylin and the
287 slides were examined under a light microscope.

288 The evaluated criteria were proliferation index, scar
289 tissue formation, and basement membrane integrity. The
290 integrity of the newly formed basement membrane was
291 determined by evaluating the percentage of anti-laminin
292 staining in the scar area.^{22,23} The proliferation index of
293 the epidermis was quantified in the scar area as the
294 percentage of Ki-67-positive cells to measure keratinocyte
295 activation. Scar formation was evaluated by counting anti-
296 α SMA positive myofibroblasts in high-power fields (average
297 of 5 fields). Anti- α SMA stain of hair follicles and in
298 smooth muscle of vessels was not counted in the analysis.²²
299 All evaluations were performed by two observers in a
300 single-blind trial under a light microscope.

301 **Ex-Vivo Bonding Force of the Healed Skin Sections**

302 After the 14-day follow-up period, the skin area containing
303 closed incisions (sutured or attached using bioadhesive)
304 was harvested under general anesthesia, using a sterile #10
305 scalpel blade, and was cut into 5 × 2 cm sections for the
306 tensile force test using a 5500 Instron Universal Testing
307 Machine with a 100 N load cell. The two parts of the skin
308 samples were strained at a constant velocity of 10 mm per
309 minute until separation was achieved. The bonding force was
310 defined as the maximum strength in the force-displacement
311 curve measured by the Instron Merlin Software. At least two
312 repetitions were carried out for each formulation.

313 **Statistical Analysis**

314 Means and standard errors of the mean (SEMs) were
315 calculated for the histologic scoring and the
316 immunohistochemical analysis and SD was calculated for the
317 bonding force analysis. Differences between means were
318 analyzed for statistical significance using a one-way
319 analysis of variance with the Tukey-Kramer multiple
320 comparisons posttest (SPSS version 17.0, IBM Corp). *P*
321 values $\leq .05$ were considered significant.

322

323 **RESULTS**

324 **Clinical Evaluation**

325 Overall, the animals tolerated the experimental procedure
326 well and did not show signs of distress or systemic or
327 local inflammation. Fourteen days post-operation,
328 macroscopic photographs were taken and clinical evaluation
329 was performed.

330 Four 10-cm incisions (two in each animal) were sutured
331 and served as a control. All four incisions demonstrated
332 good clinical appearance with a satisfactory healing
333 process and no signs of inflammation (Figure 1). Four
334 additional incisions served as the N-butyl-2-cyanoacrylate
335 control. In two of the four incisions a scab was formed and
336 the overall healing process was delayed. However, the other
337 two incisions demonstrated a good healing process. The two
338 under-healed incisions may be explained by the cytotoxic
339 nature of N-butyl-2-cyanoacrylate and its byproducts.

340 Formulation A and formulation A using a double-headed
341 syringe were applied on two incisions each. The overall
342 appearance demonstrated a poor healing process that did not
343 progress into a stable adhesion of the two adjacent
344 incision lips. Scab formation was observed in all four
345 incisions (Figure 1).

346 Formulation B demonstrated a good healing process in
347 the first animal. Therefore, the researchers elected to use
348 it in four incisions in the second pig. Five of the six
349 incisions treated with formulation B demonstrated a

350 satisfactory healing process, with good skin contact,
351 minimal scabbing, and no inflammation process (Figure 1).
352 One incision failed to heal properly, with an apparent scab
353 formation. Formulation B was also applied using a double-
354 headed syringe with a built-in stirrer in six incisions. In
355 three of the six incisions, the clinical appearance was
356 satisfactory with a good healing process. However, three
357 incisions failed to heal properly and a scab formed. The
358 relatively inferior results obtained in the three incisions
359 treated using a double-headed syringe may be explained by a
360 poor mixing process of the polymer solution and the
361 crosslinker solution.

362 **Histologic Evaluation**

363 At the study endpoint, 1 cm biopsies were taken from each
364 incision. Hematoxylin and eosin and Gomoris trichrome
365 staining for collagen fibers were performed. Clinical
366 photographs of representative incisions from the various
367 treated groups are presented in Figure 2. The following
368 criteria were independently evaluated by four observers:
369 epithelial confluence, epithelialization, clinical collagen
370 assessment, scar width, and mononuclear cell infiltrate.

371 Figure 3 presents a cumulative graph demonstrating the
372 superiority of formulation B and formulation B using a
373 double-headed syringe in comparison with formulation A.
374 Formulation B and formulation B using a double-headed

375 syringe were superior in all tested parameters compared
376 with formulation A, including improved organization of the
377 epithelium, better epithelialization, less mononuclear cell
378 infiltrate, less collagen deposition, and smaller scar
379 width. Formulation B and formulation B using a double-
380 headed syringe received general scores of 12.7 ± 2 and 10.1
381 ± 2.2 , respectively, compared with formulation A and
382 formulation A using a double-headed syringe which yielded
383 general scores of 4.2 ± 0.9 and 4.9 ± 2 , respectively. The
384 scar width of the incisions treated with formulation B did
385 not differ significantly from the control incisions that
386 were sutured (12.7 ± 2 and 13.2 ± 3 , respectively).
387 Incisions treated with formulation B had a non
388 significantly lower score compared with the incisions
389 treated with N-butyl cyanoacrylate (12.7 ± 2 and $11.7 \pm$
390 1.3 , respectively). Figure 4 presents the histologic scores
391 for all criteria. No significant differences were found in
392 the collagen organization between incisions treated with
393 formulation B, sutures, and N-butyl cyanoacrylate. Both
394 formulation A with and without the use of a double-headed
395 syringe and formulation B with the use of a double-headed
396 syringe demonstrated less-organized collagen fibers,
397 probably as a consequence of poor wound healing.

398 **Immunohistochemical Analysis**

399 Immunohistochemical staining to laminin, α SMA, and Ki67 was
400 performed to evaluate the healing process. For basement
401 membrane integrity analysis, it demonstrated a
402 nonsignificant superiority of treatment with formulation B
403 (89%) compared with sutures (79%) and N-butyl cyanoacrylate
404 (85%). Formulation A demonstrated a significant decrease in
405 laminin expression compared with formulation B (55 vs 89,
406 respectively, $P < .005$). Surprisingly, formulation A using
407 a double-headed syringe demonstrated elevated laminin
408 expression (Figures 5 and 6).

409 Scar formation was evaluated by counting anti- α SMA
410 positive myofibroblasts. Myofibroblasts are key players in
411 the reconstruction of connective tissue after injury and in
412 generating scar fibrosis, which means a less favorable
413 scar. Both formulation B and formulation B using a double-
414 headed syringe demonstrated less α SMA expression compared
415 with both A formulations. No differences were found between
416 incisions treated with formulation B, sutured incisions, or
417 incisions treated with N-butyl cyanoacrylate. Ki-67
418 staining, a marker for epidermal proliferative basal layer,
419 was performed to determine the proliferation index of the
420 epidermis and to measure keratinocyte activation. No
421 differences were found between all incisions. Nevertheless,
422 the sutured incisions (control) demonstrated a
423 significantly higher proliferation index compared with

424 incisions treated with either N-butyl cyanoacrylate or
425 bioadhesives.

426 **In Vivo Bonding Force**

427 Formulation B, which contained a relatively low EDC
428 concentration (with or without the use of a double-headed
429 syringe), demonstrated superior in vivo results compared
430 with formulation A, which contained a standard EDC
431 concentration. The bonding forces of the incision skin
432 samples are presented in Table 2.

433 The in vivo bonding force of the skin samples 14 days
434 post-operation was weakest for the sutured incisions (58
435 N), and strongest for the incisions treated with N-butyl
436 cyanoacrylate (118 N). Formulation B showed a bonding force
437 similar to that resulting from sutures (53 N); however,
438 this formulation showed a much higher bonding force when
439 applied using a double-headed syringe (80 N), although with
440 a large SD. These results are consistent with the clinical,
441 histologic, and immunohistochemical analyses.

442

443 **DISCUSSION**

444 Traditional wound-healing methods use surgical suturing
445 techniques, but this approach increases the risk of
446 infection because bacteria have an affinity for certain
447 suture materials. Further, suturing requires the use of

448 anesthesia and later suture removal. An alternative to
449 suturing that has been proposed to overcome these
450 limitations is the use of bioadhesives for nonsurgical
451 wound closure. An ideal bioadhesive should have rapid and
452 strong bonding strength to the tissue, hemostatic
453 properties, and tissue healing regeneration characteristics
454 that do not interfere with the body's natural healing
455 process. It should also be cost-effective, nontoxic,
456 degradable, and absorbable within the healing period with
457 minimal cytotoxic byproducts.

458 Cyanoacrylate-based skin adhesives are commonly
459 utilized in wound closure because of their ease of use,
460 rapid application, and ability to provide superficial
461 protection.²⁴⁻²⁶ Grimaldi et al²⁴ evaluated the incidence of
462 infection and complications of patients treated with octyl-
463 2-cyanoacrylate. They concluded that octyl-2-cyanoacrylate
464 reduces not only the risk of surgical site infections, but
465 also the timing and the number of postoperative checks,
466 thus increasing patient satisfaction. Although widely used,
467 the limitations associated with cyanoacrylates (eg,
468 toxicity of degradation byproducts, low viscosity, high
469 stiffness) make them unsuitable for long incisions and
470 restricts their usage to external or temporary
471 applications.

472 To address these limitations, the present study
473 proposes novel adhesives based on natural polymers for the
474 treatment of long surgical incisions (≥ 4 cm). The
475 researchers compared this new adhesive formulation with
476 well-established closure techniques, including surgical
477 sutures and the commercial N-butyl cyanoacrylate tissue
478 adhesive. The novel adhesive formulation is composed of
479 natural biocompatible polymers and previously demonstrated
480 high biocompatibility in both in vitro and in vivo
481 studies.^{9,14-16} In particular, the Gel-Al formulation with 20
482 mg/ml EDC exhibited excellent cell viability (above 90%) in
483 the Alamar Blue assay. The Alamar Blue assay was performed
484 on human fibroblasts that participate in the wound-healing
485 process to evaluate cell viability in the presence of the
486 hydrogels. Formulations that result in a decrease of more
487 than 30% in viability are considered cytotoxic. In
488 contrast, the commercially available adhesive tested in
489 this study, N-butyl cyanoacrylate, exhibited high
490 cytotoxicity, resulting in low cell viability of 5%.^{9,14,15}
491 These findings highlight the biocompatible nature of the
492 proposed bioadhesives, which are based on natural polymers
493 (gelatin and alginate) crosslinked by EDC and enriched with
494 layered silicates such as kaolin.

495 **Effect of the EDC Concentration**

496 The results of the clinical and histologic analyses showed
497 a superior efficacy of formulation B (low EDC content)
498 compared with formulation A (standard) in the treatment of
499 wounds. The assessment of epithelial confluence,
500 epithelialization, clinical collagen, scar width, and
501 mononuclear cell infiltrate all indicated better results
502 for formulation B. Further, immunohistochemical analysis
503 revealed higher levels of expression for laminin and Ki-67,
504 markers of epithelial integrity and proliferation,
505 respectively, in the healed tissue treated with formulation
506 B compared with formulation A. In addition, α SMA, a marker
507 for scar formation, was upregulated in formulation A
508 compared with formulation B and the control incisions. This
509 result highlights the potential advantage of formulation B
510 in reducing scar formation, a common challenge in human
511 wound healing. Based on these clinical, histologic, and
512 mechanical results, the current findings suggest that
513 formulations with lower EDC content, such as formulation B,
514 may offer improved wound healing outcomes compared with
515 formulations with higher EDC content.

516 The observed superiority of formulation B versus
517 formulation A in the present study can be explained by the
518 lower EDC (crosslinker) content in formulation B. The use
519 of a crosslinker such as EDC to enhance mechanical
520 properties and slow degradation can be advantageous.
521 However, despite being a zero-length crosslinker, in high

522 concentrations EDC may negatively impact cell migration and
523 tissue integration, therefore negatively affecting wound
524 healing.²⁷ These findings are consistent with previous
525 studies that have demonstrated the benefits of using low
526 concentrations of EDC for improving biochemical stability
527 and promoting stable wound closure. Powell et al²⁸ evaluated
528 the use of collagen-glycosaminoglycan sponges as a
529 substitute for the extracellular matrix of dermal tissue.
530 They concluded that low concentrations of EDC can
531 effectively improve the biochemical stability of the
532 collagen-glycosaminoglycan component of cultured skin
533 substitutes (CSS) and promote stable wound closure.²⁸

534 **Efficacy and Bonding Strength of the Novel Bioadhesives**

535 The results of the current clinical and histologic analyses
536 showed a slightly superior efficacy of formulation B in
537 comparison with the control, commercial N-butyl
538 cyanoacrylate. More specifically, nonsignificant elevations
539 in the histologic scoring of the epithelial confluence and
540 clinical collagen assessment were observed. Moreover,
541 results obtained from immunohistochemical analysis
542 demonstrated better (although not significant) epithelial
543 integrity, fewer α SMA positive cells, and more
544 proliferating basal epithelial cells in the incisions
545 treated with formulation B compared with those treated with
546 N-butyl cyanoacrylate.

547 N-butyl cyanoacrylate has several disadvantages in
548 comparison with the newly developed formulation B. The main
549 components of formulation B, gelatin and alginate, are both
550 natural polymers and, unlike N-butyl cyanoacrylate, do not
551 cause a foreign body reaction which may lead to local
552 ischemia, necrosis, and tissue damage. In addition, the
553 degradation of N-butyl cyanoacrylate in the tissue can
554 release certain byproducts, including formaldehyde and
555 lipid hydroperoxide; this does not occur when using the
556 biocompatible formulation B. Taken together, the slightly
557 better efficacy of formulation B, its nontoxic reactions,
558 and its cost effectiveness compared with N-butyl
559 cyanoacrylate led the researchers to conclude that
560 formulation B may serve as a potentially better alternative
561 to the FDA-approved n-butyl cyanoacrylate.

562 In comparison with sutures, most tested histologic
563 parameters for the efficacy of wound closure demonstrated
564 equal efficacy between the incisions treated with the
565 bioadhesives. Immunohistochemical analysis demonstrated a
566 slight, nonsignificant superiority in epithelial integrity
567 and fewer α SMA positive cells for formulation B. However,
568 the sutured incisions demonstrated more proliferating
569 epithelial basal cells. Suturing has several drawbacks: It
570 requires technical expertise, is time consuming for large
571 wounds, may cause injury to the physician and possible
572 transfer of infectious diseases, is painful if a local

573 anesthetic drug is not used, and results in stitch marks.
574 In contrast, the novel bioadhesives studied do not require
575 follow-up visits for removal, are less time consuming to
576 apply, and offer a potentially valuable and economical
577 approach for treating skin lacerations.

578 The superiority of formulation B was further confirmed
579 in the in vitro bonding force measurements of the skin
580 samples. The results indicated that the maximal forces in
581 tension were comparable to sutured incisions, which are
582 considered the conventional treatment method. Moreover,
583 when formulation B applied using a double-headed syringe,
584 it demonstrated even higher results, approaching the
585 maximum values (obtained for N-butyl cyanoacrylate). N-
586 butyl cyanoacrylate is known to have high bonding strength
587 to biological tissues due to its synthetic composition.
588 However, as a result of the toxicity of its degradation
589 byproducts, its low viscosity, and its high stiffness, it
590 is limited to external or temporary applications, and poses
591 a greater risk when used for larger incisions. It should be
592 noted, however, that the skin samples cut from the animals
593 varied in size and thickness. Thus, the in vivo bonding
594 force method can be considered only as a partially
595 quantitative method, which affords a rough estimate of the
596 strength of the healed tissue.

597 Previous studies have compared the clinical outcomes
598 of skin closure with octyl cyanoacrylate skin adhesive and
599 subcuticular suture closure and found no significant
600 difference in scar cosmesis and patient outcomes between
601 the two methods, although skin closure time was faster with
602 skin adhesive. These findings suggest that formulation B
603 may offer a promising alternative for wound treatment.²⁹

604 **Effect of Application Methods**

605 In this study, researchers evaluated the use of a double-
606 headed syringe as a more convenient method for future
607 clinical use. The results demonstrated that use of the
608 syringe impaired the good healing process achieved when
609 formulation B was applied to the incisions manually. The
610 relatively high SD indicates that better fitting of the
611 syringe system should be considered. Therefore, an optimal
612 syringe that is fitted especially to the bioadhesives may
613 lead to better results.

614 **Limitations**

615 The limitations of this study are inherent to this kind of
616 study design and use of large animals for in vivo study and
617 include a small sample size and brief follow-up period.
618 Therefore, the results of this study may serve as a
619 preliminary experimental model for further investigation of
620 the newly proposed hydrogels when applied to human skin
621 closure. Further research with larger sample sizes, longer

622 follow-up periods, and broader comparisons to various
623 closure techniques is warranted to fully understand the
624 limitations and potential benefits of the bioadhesive in
625 clinical practice.

626 **Practice Implications and Recommendations for Further Study**

627 In terms of clinical implications, the current study
628 provides valuable insights into the comparative
629 effectiveness of skin adhesives versus sutures and
630 commercial adhesive N-butyl-2-cyanoacrylate for wound
631 closure applications. The results suggest that the
632 formulation B bioadhesive may be a viable alternative to
633 current treatments with comparable healing and cosmetic
634 outcomes and demonstrated no adverse effects on the skin
635 structures. This information can guide clinicians in
636 choosing the most appropriate method for wound closure,
637 considering factors such as patient comfort, wound size,
638 and potential complications.

639 Despite the promising results from the current study,
640 further research is needed with larger sample sizes. This
641 would help to assess the effectiveness, safety, and cost
642 implications of using different skin adhesives compared
643 with sutures and N-butyl-2-cyanoacrylate. Such studies
644 would provide more robust evidence and facilitate the
645 implementation of these methods in clinical practice.

646 The potential time-saving aspect of using skin
647 adhesives rather than sutures is promising. Eliminating the
648 need for suture removal and reducing the complexity of the
649 closure process may lead to time savings, decreased
650 healthcare costs, and increased efficiency in wound
651 management. In terms of practice implications, the current
652 research suggests that skin adhesives may offer a valuable
653 alternative to traditional sutures for wound closure. This
654 could lead to enhanced patient experience, reduced pain,
655 and improved healing outcomes. However, further research is
656 needed to explore specific clinical guidelines, training
657 requirements, and regulatory considerations to ensure the
658 safe and effective implementation of these methods in
659 different healthcare settings.

660

661 **CONCLUSIONS**

662 This study demonstrated the efficacy of a novel bioadhesive
663 for the closure of large incisions in a porcine skin model.
664 This newly developed bioadhesive may serve as a less toxic
665 and more tolerable alternative to FDA-approved bioadhesives
666 commonly used in clinical practice and may also replace the
667 need for suturing large incisions. Eliminating the need for
668 suture removal and reducing the complexity of the closure
669 process may lead to time savings, decreased healthcare
670 costs, and increased efficiency in wound management. The

671 outcome of this study can be seen as a preliminary
672 experimental model for further exploration of the
673 application of the current bioadhesive in human skin
674 closure. However, further research is needed to ensure the
675 safe and effective implementation of these methods in
676 different healthcare settings.

677

678 **References**

- 679 1. Bouten PJM, Zonjee M, Bender J, et al. The Chemistry of Tissue Adhesive
680 Materials. *Prog Polym Sci* 2014; doi: 10.1016/j.progpolymsci.2014.02.001.
- 681 2. Sibert JR, Maddocks GB, Brown BM. Childhood accidents: An endemic of
682 epidemic proportions. *Arch Dis Child* 1981; doi: 10.1136/adsc.56.3.225.
- 683 3. Reece TB, Maxey TS, Kron IL. A prospectus on tissue adhesives. *Am J Surg* 2001;
684 doi: 10.1016/S0002-9610(01)00742-5.
- 685 4. Singer AJ, Perry L. A comparative study of the surgically relevant mechanical
686 characteristics of the topical skin adhesives. *Academic Emergency Medicine*
687 2012;19(11); doi: 10.1111/acem.12009.
- 688 5. Mehdizadeh M, Yang J. Design Strategies and Applications of Tissue
689 Bioadhesives. *Macromol Biosci* 2013; doi: 10.1002/mabi.201200332.
- 690 6. Ge L, Chen S. Recent Advances in Tissue Adhesives for Clinical Medicine.
691 *Polymers (Basel)* 2020;12(4); doi: 10.3390/POLYM12040939.
- 692 7. Sanders L, Nagatomi J. Clinical applications of surgical adhesives and sealants.
693 *Crit Rev Biomed Eng* 2014;42(3–4); doi: 10.1615/CritRevBiomedEng.2014011676.
- 694 8. Pinkas O, Zilberman M. Novel gelatin–alginate surgical sealants loaded with
695 hemostatic agents. *International Journal of Polymeric Materials and Polymeric*
696 *Biomaterials* 2017; doi: 10.1080/00914037.2016.1233415.
- 697 9. Pinkas O, Goder D, Noyvirt R, et al. Structuring of composite hydrogel
698 bioadhesives and its effect on properties and bonding mechanism. *Acta Biomater*
699 2017; doi: 10.1016/j.actbio.2017.01.047.
- 700 10. Kuijpers AJ, Engbers GHM, Krijgsveld J, et al. Cross-linking and characterisation of
701 gelatin matrices for biomedical applications. *J Biomater Sci Polym Ed*
702 2000;11(3):225–243; doi: 10.1163/156856200743670.

- 703 11. Gelatin Manufacturers Institute of America. Gelatin Handbook GMIA. 2012.
- 704 12. Haug A, Larsen B, Smidsrød O, et al. Studies on the Sequence of Uronic Acid
705 Residues in Alginic Acid. *Acta Chem Scand* 1967; doi:
706 10.3891/acta.chem.scand.21-0691.
- 707 13. Gombotz WR, Wee SF. Protein Release from Alginate Matrices. *Adv Drug Deliv*
708 *Rev* 2012; doi: 10.1016/j.addr.2012.09.007.
- 709 14. Eshkol-Yogev I, Kaufman A, Haddad M, et al. Cell viability of novel composite
710 hydrogels loaded with hydroxyapatite for oral and maxillofacial bone
711 regeneration. *Odontology* 2022;110(2); doi: 10.1007/s10266-021-00662-9.
- 712 15. Eshkol-Yogev I, Gilboa E, Giladi S, et al. Formulation - Properties effects of novel
713 dual composite hydrogels for use as medical sealants. *Eur Polym J* 2021;152; doi:
714 10.1016/j.eurpolymj.2021.110470.
- 715 16. Eshkol-Yogev I, Tobias T, Keren A, et al. Dual composite bioadhesives for wound
716 closure applications: An in vitro and in vivo study. *Polym Adv Technol*
717 2022;33(11); doi: 10.1002/pat.5691.
- 718 17. Foox M, Raz-Pasteur A, Berdicevsky I, et al. In vitro microbial inhibition, bonding
719 strength, and cellular response to novel gelatin-alginate antibiotic-releasing soft
720 tissue adhesives. *Polym Adv Technol* 2014;25(5); doi: 10.1002/pat.3278.
- 721 18. Cohen B, Pinkas O, Foox M, et al. Gelatin-alginate novel tissue adhesives and
722 their formulation-strength effects. *Acta Biomater* 2013; doi:
723 10.1016/j.actbio.2013.07.002.
- 724 19. Sullivan TP, Eaglstein WH, Davis SC, et al. The Pig as a Model for Human Wound
725 Healing. *Wound Repair and Regeneration* 2001;9(2); doi: 10.1046/j.1524-
726 475X.2001.00066.x.
- 727 20. Zeplin PH, Schmidt K, Laske M, et al. Comparison of various methods and
728 materials for treatment of skin laceration by a 3-dimensional measuring
729 technique in a pig experiment. *Ann Plast Surg* 2007; doi:
730 10.1097/01.sap.0000245135.58229.e7.
- 731 21. Hollander DA, Erli HJ, Theisen A, et al. Standardized qualitative evaluation of scar
732 tissue properties in an animal wound healing model. *Wound Repair and*
733 *Regeneration* 2003; doi: 10.1046/j.1524-475X.2003.11212.x.
- 734 22. Andree C, Reimer C, Page CP, et al. Basement membrane formation during
735 wound healing is dependent on epidermal transplants. *Plast Reconstr Surg* 2001;
736 doi: 10.1097/00006534-200101000-00015.
- 737 23. Loeffelbein DJ, Baumann C, Stoeckelhuber M, et al. Amniotic membrane as part
738 of a skin substitute for full-thickness wounds: An experimental evaluation in a
739 porcine model. *J Biomed Mater Res B Appl Biomater* 2012; doi:
740 10.1002/jbm.b.32689.

- 741 24. Harsha Kathpalia, Vasudha Prabhu SM. CYANOACRYLATES : AN OVERVIEW IN ITS
742 APPLICATION AS A TISSUE. European journal of pharmaceutical and medical
743 research 2019;6(3).
- 744 25. Grimaldi L, Cuomo R, Brandi C, et al. Octyl-2-cyanoacrylate adhesive for skin
745 closure: Eight years experience. In Vivo (Brooklyn) 2015;29(1).
- 746 26. Amiel GE, Sukhotnik I, Kowar B, et al. Use of N-butyl-2-cyanoacrylate in elective
747 surgical incisions - Longterm outcomes. J Am Coll Surg 1999;189(1); doi:
748 10.1016/S1072-7515(99)00068-X.
- 749 27. Bax D V., Davidenko N, Gullberg D, et al. Fundamental insight into the effect of
750 carbodiimide crosslinking on cellular recognition of collagen-based scaffolds.
751 Acta Biomater 2017;49; doi: 10.1016/j.actbio.2016.11.059.
- 752 28. Powell HM, Boyce ST. Wound closure with EDC cross-linked cultured skin
753 substitutes grafted to athymic mice. Biomaterials 2007;28(6); doi:
754 10.1016/j.biomaterials.2006.10.011.
- 755 29. Martin JG, Hollenbeck ST, Janas G, et al. Randomized Controlled Trial of Octyl
756 Cyanoacrylate Skin Adhesive versus Subcuticular Suture for Skin Closure after
757 Implantable Venous Port Placement. Journal of Vascular and Interventional
758 Radiology 2017; doi: 10.1016/j.jvir.2016.08.009.

759

760

761 **Figure legends**

762 Figure 1.

763 **REPRESENTATIVE INCISIONS FROM EACH GROUP, 14 DAYS POST-**
764 **OPERATION**

765 Control groups were sutures and N-butyl-2-cyanoacrylate.

766 The bioadhesive formulations were Formulation A,

767 Formulation A using a double-headed syringe, Formulation B,

768 and Formulation B using a double-headed syringe.

769

770 Figure 2.

771 **REPRESENTATIVE HISTOLOGIC SECTIONS OF INCISIONS FROM EACH**
772 **GROUP, 14 DAYS POST-OPERATION**

773 Hematoxylin and eosin staining (Upper), Trichrome staining
774 for collagen fibers (lower).

775

776

777 Figure 3.

778 **HISTOLOGIC SCORING**

779 Cumulative graph presenting the scoring of four independent
780 observers for the following criteria: epithelial
781 confluence, epithelialization, clinical collagen
782 assessment, scar width, and mononuclear cell infiltrate.

783 Grading was on a scale from 0 to 5: 0 = absence, 1 =
784 minimal presence, 2 = mild presence, 3 = moderate presence,
785 4 = high presence, and 5 = extensive presence.

786

787 Figure 4.

788 **HISTOLOGIC SCORING OF BIOPSIES TAKEN FROM THE INCISIONS 14**
789 **DAYS POST-OPERATION**

790 The following healing criteria were investigated:
791 epithelial confluence, epithelialization, clinical collagen
792 assessment, scar width, and mononuclear infiltrate.

793

794 Figure 5.

795 **REPRESENTATIVE IMMUNOHISTOCHEMISTRY SECTIONS OF INCISIONS**
796 **FROM EACH GROUP, 14 DAYS POST-OPERATION.**

797 Abbreviation: α SMA, smooth muscle actin.

798

799 Figure 6.

800 **QUANTIFICATION OF THE IMMUNOHISTOCHEMICAL STAINING: (A)**
801 **Basement membrane integrity (laminin expression), (B) SMA**
802 **expression, (C) Ki-67 expression.**

803

804 Abbreviation: α SMA, smooth muscle actin.

805